KR0137476B1 - 조산아의뇌실내출혈방지용치료제 - Google Patents

조산아의뇌실내출혈방지용치료제

Info

Publication number
KR0137476B1
KR0137476B1 KR1019890002127A KR890002127A KR0137476B1 KR 0137476 B1 KR0137476 B1 KR 0137476B1 KR 1019890002127 A KR1019890002127 A KR 1019890002127A KR 890002127 A KR890002127 A KR 890002127A KR 0137476 B1 KR0137476 B1 KR 0137476B1
Authority
KR
South Korea
Prior art keywords
factor xiii
factor
precipitate
intraventricular
bleeding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019890002127A
Other languages
English (en)
Korean (ko)
Other versions
KR890012659A (ko
Inventor
아끼라 시라하따
미노루 우찌다
사또시 다나까
게니찌로 쭈무라
Original Assignee
아다찌 가쭈오
훽스트 제팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다찌 가쭈오, 훽스트 제팬 리미티드 filed Critical 아다찌 가쭈오
Publication of KR890012659A publication Critical patent/KR890012659A/ko
Application granted granted Critical
Publication of KR0137476B1 publication Critical patent/KR0137476B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019890002127A 1988-02-24 1989-02-23 조산아의뇌실내출혈방지용치료제 Expired - Lifetime KR0137476B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤
JP?63-39646 1988-02-24
JP63-39646 1988-02-24

Publications (2)

Publication Number Publication Date
KR890012659A KR890012659A (ko) 1989-09-18
KR0137476B1 true KR0137476B1 (ko) 1998-06-01

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002127A Expired - Lifetime KR0137476B1 (ko) 1988-02-24 1989-02-23 조산아의뇌실내출혈방지용치료제

Country Status (12)

Country Link
US (1) US5114916A (enExample)
EP (1) EP0330049B1 (enExample)
JP (1) JPH01216939A (enExample)
KR (1) KR0137476B1 (enExample)
AT (1) ATE94070T1 (enExample)
AU (1) AU613154B2 (enExample)
CA (1) CA1332352C (enExample)
DE (1) DE68908913T2 (enExample)
DK (1) DK174978B1 (enExample)
ES (1) ES2059588T3 (enExample)
IE (1) IE63656B1 (enExample)
PT (1) PT89802B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
EP0624095B2 (en) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Methods and compositions for reducing blood loss
WO1993020837A1 (fr) * 1992-04-21 1993-10-28 Ajinomoto Co., Inc. Remede contre les plaies
DE69326349T2 (de) * 1992-11-12 2000-03-02 Mayberg, Marc R. Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
US8461302B2 (en) * 2004-11-23 2013-06-11 Zymogenetics, Inc. Purification of recombinant human factor XIII
TWI418564B (zh) * 2005-04-11 2013-12-11 沙凡特藥品公司 利用陽離子界面活性劑之蛋白質純化
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
KR101288027B1 (ko) * 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DK175919B1 (da) * 1986-09-19 2005-06-27 Univ Washington Ekspression af biologisk aktiv faktor XIII

Also Published As

Publication number Publication date
JPH0378850B2 (enExample) 1991-12-17
PT89802B (pt) 1994-04-29
EP0330049B1 (en) 1993-09-08
DE68908913T2 (de) 1994-01-27
KR890012659A (ko) 1989-09-18
ATE94070T1 (de) 1993-09-15
IE63656B1 (en) 1995-05-31
DE68908913D1 (de) 1993-10-14
US5114916A (en) 1992-05-19
PT89802A (pt) 1989-10-04
EP0330049A2 (en) 1989-08-30
JPH01216939A (ja) 1989-08-30
EP0330049A3 (en) 1991-01-30
AU613154B2 (en) 1991-07-25
CA1332352C (en) 1994-10-11
AU3024389A (en) 1989-08-24
ES2059588T3 (es) 1994-11-16
DK174978B1 (da) 2004-04-05
IE890580L (en) 1989-08-24
DK83889A (da) 1989-08-25
DK83889D0 (da) 1989-02-23

Similar Documents

Publication Publication Date Title
US4340589A (en) Antithrombin preparation and process for the production thereof
US4960757A (en) Pasteurized human fibrinogen (HF), a process for its preparation, and its use
US5114916A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
EP0326014A1 (en) Composition of anticoagulants
JP2532535B2 (ja) 組織タンパクｐｐ４含有医薬
KR100255095B1 (ko) 유산 위험 치료제
EP0124018B1 (en) Pharmaceutical preparation containing purified fibronectin
JPH01151514A (ja) 神経疾患治療・予防剤
EP0278416B1 (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
JPWO1997035609A1 (ja) 組織因子凝固系インヒビター含有血管新生阻害剤
AU674061B2 (en) Factor XIII for treatment of skin wounds
US5164373A (en) Therapeutic agent for diabetic gangrene comprising factor XIII
JPH07502989A (ja) 血友病の治療
Green Factor VIII (anti-hemophilic factor)
JP2698782B2 (ja) 脳動脈瘤破裂防止剤
JPH08295635A (ja) 胎盤血流量改善剤
JOHNSON et al. of a Factor VIII Concentrateđ
JPH0769921A (ja) 網膜血管閉塞症予防治療剤
JPH09176041A (ja) α２プラスミンインヒビターを含有するＤＩＣ治療用薬剤

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890223

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940223

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890223

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970930

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19971126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980209

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980209

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20001229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020111

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030123

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040120

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050121

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060126

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070125

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080122

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20090123

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20100204

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20101228

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20120202

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20120202

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20131022

Termination category: Expiration of duration